December 1, 2007
By:Eric S. Langer
China's pharma industry represents 5% of the world total. By 2010, China is expected to become the world's fifth largest pharmaceutical market.
 |
November 1, 2007
By:Eric S. Langer, Eliza Yibing Zhou
Biotechnology is definitely a hot topic in China—the country's administrators recently identified it as a "cornerstone of China's national economy by 2020." But most realize that getting there will require a better trained, specialized workforce than currently exists. The Chinese government has been pumping money into life sciences education as part of its plan to achieve a global biotechnological presence over the next 15 years.
|
August 1, 2007
By:Eric S. Langer
In 2006, China exported a total of $890 million in biologics to other countries—a 30.61% increase, compared with the previous year.
|
July 1, 2007
By:Eric Langer, Eliza Yibing Zhou
Most Chinese biopharmaceuticals are relatively small and there are not enough of them to sustain a robust services sector.
|
June 1, 2007
By:Eric S. Langer
In China, the presence of a substantial biogenerics industry reflects a growing need to provide healthcare to domestic populations, at a reasonable cost.
|
May 1, 2007
By:Eric S. Langer
China's central government is aware of the need to improve intellectual property protection and enforcement.
|
April 1, 2007
By:Eliza Yibing Zhou
The Chinese vaccine market competition is now transferring from the former price-competition model to a technology- competition model.
|
March 1, 2007
By:Eliza Yibing Zhou
The Chinese government's investments in the biopharmaceutical sector may help it become one of the leading industries in China by 2020.
|
February 1, 2007
By:Eliza Yibing Zhou
China today represents a $15-billion market for pharmaceutical products. China's pharmaceutical industry has been expanding at about 20% over the past five years. It has been predicted that China will become the world's fifth largest single pharmaceutical market by 2010. With such a fast-growing market segment and a huge population, simply getting pharmaceuticals to the patients and healthcare providers is becoming a daunting task. Biopharmaceuticals distributers face the same challenge, with the added complications associated with cold-chain management, shelf-life, and product stability.
|
| 
